TNG260 not checked

Tango Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Main trialPhase 1/2
“The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.”In the company’s words, NCT05887492 on ClinicalTrials.gov

Other drugs for Non Small Cell Lung Cancer

All 561 drugs for Non Small Cell Lung Cancer

Coming up0

No dates coming up.

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 22 Sep 2026 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TNG260

Following is part of Solo: you see every change to TNG260 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in